$TSHA
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
Healthcare
Sector
Biotechnology
Industry
Sean Nolan
CEO
73
Employees
$4.40
Current Price
$1.10B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 7 | $1,880,187.54 | 398,623 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 8 | $2,822,187.54 | 598,623 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Feb 4, 2026 | Alam Kamran CHIEF FINANCIAL OFFICER | Sale | 1,655 | $4.52 | $7,480.60 | View Details |
| Jan 26, 2026 | Nagendran Sukumar Director | Sale | 26,918 | $4.61 | $124,091.98 | View Details |
| Jan 23, 2026 | Nagendran Sukumar Director | Sale | 89,132 | $4.75 | $423,377.00 | View Details |
| Jan 26, 2026 | Nolan Sean P. Director | Sale | 41,312 | $4.61 | $190,448.32 | View Details |
| Jan 23, 2026 | Nolan Sean P. Director | Sale | 136,789 | $4.75 | $649,747.75 | View Details |
| Jan 26, 2026 | Alam Kamran CHIEF FINANCIAL OFFICER | Sale | 23,849 | $4.61 | $109,943.89 | View Details |
| Jan 23, 2026 | Alam Kamran CHIEF FINANCIAL OFFICER | Sale | 78,968 | $4.75 | $375,098.00 | View Details |
| Jan 12, 2026 | Nagendran Sukumar Director | Sale | 200,000 | $4.71 | $942,000.00 | View Details |
6 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
Estimated-$0.10
Actual-$0.08
Beat
Revenue
Estimated$1.07M
Actual$5.49M
Beat
EPS
Estimated-$0.09
ActualN/A
Revenue
Estimated$1.89M
ActualN/A
EPS
Estimated-$0.11
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies: